HelixNews
LatestWeekLocalBlindspot

1 source covering

SELLAS Life Sciences posts $10.1M Q3 loss as pivotal leukemia trial results approach

Crypto Briefing ·

SELLAS' financial loss underscores the high stakes of its leukemia trials, potentially impacting future funding and strategic directions.

Read at Crypto Briefing

Who's covering it

  1. Crypto BriefingSELLAS Life Sciences posts $10.1M Q3 loss as pivotal leukemia trial results approachSELLAS' financial loss underscores the high stakes of its leukemia trials, potentially impacting future funding and strategic directions.